NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹163 Cr | ₹118 Cr | ₹87 Cr | ₹58 Cr | ₹66 Cr |
What is the latest Total Current Liabilities ratio of NGL FINECHEM ?
| Year | Total Current Liabilities |
|---|---|
| Mar2026 | ₹163 Cr |
| Mar2025 | ₹118 Cr |
| Mar2024 | ₹87 Cr |
| Mar2023 | ₹58 Cr |
| Mar2022 | ₹66 Cr |
How is Total Current Liabilities of NGL FINECHEM Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹163 Cr | 37.30 | |
| Mar2025 | ₹118 Cr | 36.77 | |
| Mar2024 | ₹87 Cr | 48.54 | |
| Mar2023 | ₹58 Cr | -11.21 | |
| Mar2022 | ₹66 Cr | - | |
Compare Total Current Liabilities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,921.9 Cr | 7.8% | 5.5% | 116.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹432,120.0 Cr | -3.2% | -5.4% | 12% | Stock Analytics | |
| DIVIS LABORATORIES | ₹253,390.0 Cr | 0.7% | 3.2% | 61.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹181,740.0 Cr | -2.8% | -3% | 32.6% | Stock Analytics | |
| CIPLA | ₹108,497.0 Cr | -2.9% | -3.3% | -10.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,925.0 Cr | -3.3% | 4.7% | -2.2% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | 7.8% |
5.5% |
116.2% |
| SENSEX | -2.1% |
-5.9% |
-10.8% |
You may also like the below Video Courses